Distinguishing Mechanical from Inflammatory Joint Symptoms

Introduction to Diagnostic Challenges

The European League Against Rheumatism (EULAR) guidelines emphasize the importance of establishing the presence or absence of inflammation before treatment decisions, as persistence of symptoms without inflammatory activity makes DMARD therapy ineffective, leading to apparent treatment failures 1, 2
The 2022 EULAR guidelines recommend considering the possibility of misdiagnosis or coexistent mimicking disease before escalating therapy in presumed difficult-to-treat RA 1, 2

Inflammatory arthritis features include morning stiffness lasting >30 minutes or after prolonged inactivity, soft tissue swelling on examination, symmetric involvement of MCP and PIP joints with DIP joints typically spared, and pain that improves with activity 3, 4
Mechanical/osteoarthritis features include stiffness that occurs with joint activity, not after rest, bony enlargement rather than soft tissue swelling, DIP joint involvement, and pain that worsens with weight-bearing or activity 3, 4, 5

Osteoarthritis can coexist with or be mistaken for inflammatory arthritis 1, 2, 6
Fibromyalgia heightens pain and symptom scores despite the absence of true inflammation 1, 2, 6
Crystal arthropathies, such as gout or pseudogout, can mimic seronegative RA 1, 2
Psoriatic arthritis, especially when skin findings are subtle, can be mistaken for seronegative RA 1, 3, 7
Polymyalgia rheumatica can also mimic seronegative RA 1, 6

When clinical assessment and composite disease activity indices are equivocal, ultrasonography should be used to detect true inflammatory activity, as recommended by the 2022 EULAR guidelines 1, 2, 6
Ultrasonography detects synovial thickening and power Doppler signal indicating active inflammation 1, 2, 6

In the absence of confirmed inflammatory activity, DMARD therapy should not be escalated, and careful tapering should be considered, according to the 2022 EULAR guidelines 1, 2
The 2022 EULAR guidelines achieved 78% consensus on this principle, emphasizing that escalating immunosuppression for non-inflammatory symptoms leads to ineffective treatment and unnecessary toxicity risk 1, 2

Do not rely solely on composite disease activity scores in patients with obesity or fibromyalgia, as these conditions artificially elevate scores without true inflammation 1, 6
Do not assume all joint symptoms in a patient with a prior RA diagnosis are from active RA - osteoarthritis and other mechanical conditions commonly coexist 1, 2, 6
Do not continue escalating DMARDs without confirming inflammation, as this leads to polypharmacy without benefit 1, 2